MONASH IVF GROUP LIMITED (MVF)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVF

MVF - MONASH IVF GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.25
Index: ASX300 | ALL-ORDS

Monash IVF is an Australian provider of IVF, Ultrasound and genetic testing services throughout Australia and Asia. The company has been listed since 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.79

04 Aug
2025

-0.010

OPEN

$0.80

-1.25%

HIGH

$0.80

921,275

LOW

$0.79

TARGET
$1.10 39.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MDR . MPL . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
MVF: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.7 7.3 xxx
DPS (cps) xxx 5.0 4.9 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx 13.6% - 3.0% xxx
PE Ratio xxx N/A 11.1 xxx
Dividend Yield xxx N/A 6.0% xxx
Div Pay Ratio(%) xxx N/A 66.7% xxx

Dividend yield today if purchased 3 years ago: 4.76%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 6.17

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/03 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic 7.94.66.54.75.6-1.7
DPS All 5.62.04.24.44.45.0
Sales/Revenue 152.0 M145.4 M183.6 M192.3 M213.6 M255.0 M
Book Value Per Share 68.664.168.468.870.162.1
Net Operating Cash Flow 29.5 M26.5 M43.3 M31.3 M38.0 M50.0 M
Net Profit Margin 13.06 %8.06 %13.70 %9.57 %10.22 %-2.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed 11.68 %5.54 %9.74 %6.89 %8.07 %-2.53 %
Return on Invested Capital 7.54 %4.14 %8.24 %5.72 %6.20 %-1.77 %
Return on Assets 6.75 %3.62 %7.07 %4.95 %5.40 %-1.40 %
Return on Equity 11.68 %5.54 %9.74 %6.89 %8.07 %-2.53 %
Return on Total Capital 12.39 %5.93 %11.16 %9.34 %9.70 %11.02 %
Free Cash Flow ex dividends 9.8 M12.0 M20.2 M2.8 M-7.0 M10.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt 0 M2 M7 M7 M6 M8 M
Long Term Debt 88 M55 M39 M70 M94 M127 M
Total Debt 88 M58 M46 M77 M100 M135 M
Goodwill - Gross 231 M233 M233 M233 M255 M273 M
Cash & Equivalents - Generic 4 M15 M9 M8 M8 M11 M
Price To Book Value 1.900.831.241.371.632.07

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex 6.5 M7.5 M10.0 M11.8 M27.8 M21.7 M
Capex % of Sales 4.30 %5.16 %5.46 %6.12 %13.01 %8.50 %
Cost of Goods Sold 95 M107 M126 M135 M150 M180 M
Selling, General & Admin. Exp & Other 25 M21 M22 M26 M28 M33 M
Research & Development ------
Investments - Total 1 M0 M1 M1 M2 M2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

16/06/2025

1

Buy

$0.95

20.25%

Following a second embryo mix-up incident at Monash IVF and the subsequent resignation of its CEO, Ord Minnett highlights several risks to the company's outlook.

They include weaker new patient volumes, likely loss of medical staff, higher opex and increased regulation. As a result, the broker downgraded FY26-27 EPS by -13-14%.

Still, the analyst maintained the Buy rating as a 10x FY27 price-earnings multiple is regarded as an attractive entry point.

Target cut to $0.95 from $1.05.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 4.70 cents and EPS of 7.40 cents.
Ord Minnett forecasts a full year FY26 dividend of 3.90 cents and EPS of 5.80 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

12/06/2025

1

Overweight

$1.25

58.23%

The analysts at Wilsons express concern over reputational risk for Monash IVF following a second embryo transfer error, this time at its Clayton laboratory, disclosed in June 2025. (Indeed, Chief Executive Michael Knaap has since resigned).

The broker highlights the close timing of this incident with a prior Brisbane clinic error could weigh on short-term Australian market share, despite management's assurance the two events occurred years apart.

The company has launched an internal investigation, extended the scope of an existing independent review, notified ART regulators, and will temporarily enhance verification procedures beyond standard practice.

The broker notes FY25 guidance for underlying profit of circa $27.5m remains unchanged, and insurance coverage is expected to mitigate financial impact.

Wilsons makes no changes to financial forecasts but places its Overweight rating and $1.25 target under review.

FORECAST
Wilsons forecasts a full year FY25 dividend of 4.80 cents and EPS of 6.90 cents.
Wilsons forecasts a full year FY26 dividend of 5.00 cents and EPS of 7.10 cents.
Access Extra Coverage Research History >

MVF STOCK CHART

FNArena News on MVF

1
Rudi’s View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

Jul 24 2025 - Rudi's View
2
Rudi’s View: Aussie Broadband, oOh!media, Paladin Energy, Seek, Xero & More

Jul 17 2025 - Rudi's View
3
Rudi’s View: Gold stocks & Miners, DigiCo, Pinnacle & More

Jul 10 2025 - Rudi's View
4
Rudi’s View: The Megatrend You Simply Cannot Ignore

Jul 09 2025 - Rudi's View
5
Rudi’s View: Charter Hall, Droneshield, Pinnacle, WiseTech & More

Jul 03 2025 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps